These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15600052)

  • 1. [Moxifloxacin in general practice. Economical concept].
    MMW Fortschr Med; 2004 Nov; 146(46):57. PubMed ID: 15600052
    [No Abstract]   [Full Text] [Related]  

  • 2. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gigantic study planned. 100,000 patients with COPD test general practice antibiotic].
    MMW Fortschr Med; 2004 Mar; 146(10):41. PubMed ID: 15347081
    [No Abstract]   [Full Text] [Related]  

  • 4. [Respiratory tract infections. Increasingly more established antibiotics fail].
    MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534005
    [No Abstract]   [Full Text] [Related]  

  • 5. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 6. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN; Friedman HS; Perfetto EM
    Curr Med Res Opin; 2006 Feb; 22(2):327-33. PubMed ID: 16466604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
    Med Lett Drugs Ther; 2004 Mar; 46(1179):25-7. PubMed ID: 15057188
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of respiratory tract infections with moxifloxacin: results of postmarketing surveillance in China.
    Liu LY; Landen H
    Int J Clin Pract; 2007 Sep; 61(9):1509-15. PubMed ID: 17635617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood test may lower antibiotic usage in lower respiratory tract infections.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Mar; 15(6):1, 8-9. PubMed ID: 15040383
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
    Jensen MK; Fiscella RG
    Am J Health Syst Pharm; 2006 Sep; 63(17):1637-40. PubMed ID: 16914634
    [No Abstract]   [Full Text] [Related]  

  • 12. 10 years' experience with the pneumococcal quinolone moxifloxacin.
    Burkhardt O; Welte T
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):645-68. PubMed ID: 19681692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
    Martin M; Moore L; Quilici S; Decramer M; Simoens S
    Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic anaphylaxis caused by moxifloxacin.
    Sánchez-Morillas L; Rojas Pérez-Ezquerra P; Reaño-Martos M; Laguna-Martínez JJ; Gómez-Tembleque P
    Allergol Immunopathol (Madr); 2010; 38(4):226-7. PubMed ID: 20089346
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of moxifloxacin in the treatment of respiratory tract infections: the Croatian post-marketing study].
    Kuzman I; Kincl-Brodnjak V; Ermakora S; Kovacević D; Kuzman T
    Lijec Vjesn; 2005; 127(3-4):77-81. PubMed ID: 16193858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based review of moxifloxacin.
    O'Brien TP
    Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin.
    Johnson P; Adelglass J; Rankin B; Sterling R; Keating K; Benson A; Pertel P
    Int J Clin Pract; 2008 Sep; 62(9):1366-72. PubMed ID: 18671753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Moxifloxacin: results of clinical use].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antibiotic therapy of respiratory tract infections. Rapid and good effectiveness].
    MMW Fortschr Med; 2004 Nov; 146(46):56-7. PubMed ID: 15600051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.